Elanco Animal Health Inc. — Q1 2023 Form 10-Q
Business context and reporting period
Elanco develops, manufactures and markets animal-health products for pets and farm animals in more than 90 countries. This unaudited report covers the three months ended March 31, 2023; the comparable period is Q1 2022. The company reports as one operating segment.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | $1.257 billion | $1.226 billion |
| Income before taxes | $108 million | $75 million |
| Net income | $103 million | $51 million |
| Diluted EPS | $0.21 | $0.10 |
| Operating cash flow | $(145) million | $(62) million |
- Revenue rose 3% reported and 6% at constant exchange rates. Pet Health revenue increased 5% to $675 million; Farm Animal increased 1% to $573 million. Contract manufacturing revenue fell to $9 million from $17 million.
- Gross profit was $763 million, with gross margin of approximately 61%, compared with $717 million and approximately 58% in Q1 2022. Cost of sales was 39% of revenue versus 42%.
- Interest expense increased 23% to $64 million, primarily due to higher rates on variable-rate debt. The effective tax rate was 4.4%, down from 31.6%.
- Cash used in investing activities was $55 million; cash provided by financing activities was $174 million, including a $200 million revolving-credit-facility draw. Cash declined $27 million to $318 million.
- At March 31, 2023, total debt was $6.020 billion, including $381 million current and $5.639 billion long-term; debt increased from $5.836 billion at year-end 2022. Current assets were $3.548 billion and current liabilities $1.578 billion.
Material changes versus the prior period
- Net income more than doubled, while revenue grew modestly. Lower cost of sales and a substantially lower tax expense contributed to the earnings increase; higher interest expense partly offset it.
- Operating cash use worsened by $83 million, primarily reflecting changes in operating assets and liabilities, particularly receivables and inventories. Receivables rose to $1.051 billion from $797 million and inventories to $1.596 billion from $1.538 billion.
- Reported Q1 revenue included an estimated $90 million to $110 million shifted forward from Q2 as customers changed purchasing patterns ahead of the Bayer Animal Health ERP integration. The filing also says payment terms were extended on approximately $35 million of Q1 sales in certain international markets.
- Approximately 17.2 million shares were issued when the tangible equity units converted in February 2023. The TEU amortizing notes matured that month.
Outlook, risks and unusual items
- The filing provides no clear numerical full-year guidance. Management expects macroeconomic pressures, including inflation, higher interest rates, supply-chain disruption and consumer volatility, to continue in 2023. It notes reduced demand and retailer destocking, particularly affecting parasiticide products.
- The ERP integration was expected to finish in Q2 2023. Associated shipping blackout periods may affect revenue and working capital; management describes the Q1 revenue shift as an estimate.
- Q1 included $40 million of asset impairment, restructuring and other special charges, primarily Bayer integration and systems costs. NutriQuest acquisition revenue and income were immaterial; the acquisition included $35 million of recognized contingent consideration, with up to $85 million potentially payable on milestones.
- Risks include substantial indebtedness, variable interest rates, competition and generics, foreign exchange, product safety and regulatory exposure, and the ability to realize integration savings. Credit rating agencies downgraded the company’s ratings in February, March and April 2023; the filing says downgrades of certain notes require additional interest.
- Seresto-related litigation and regulatory attention remain ongoing. The company also disclosed an SEC subpoena concerning pre-mid-2020 channel inventory and sales practices; it says it is cooperating and cannot estimate a potential loss. It reported no material litigation liabilities established at quarter-end.
- Management concluded disclosure controls remained ineffective because of a material weakness involving review of the annual income-tax provision, including deferred-tax valuation allowances. Remediation was ongoing and could not be considered complete until effectiveness was assessed for 2023.
- The company expects approximately $378 million of minimum lease payments over 25 years for its new headquarters, with commencement expected in 2025. It also reported a pending NutriQuest Brazil transaction with $24 million of stated consideration.
Important facts for investors to verify
- How much of Q1 growth reflected revenue shifted from Q2, and how the ERP integration and shipping blackout affected Q2 sales, collections and inventory.
- Whether operating cash flow improves as receivables and inventory normalize, and how much working capital the business requires.
- Debt maturity, refinancing and covenant capacity, the cost of rating-related interest increases, and sensitivity to variable rates despite hedging.
- Progress in remediating the income-tax control weakness and any subsequent disclosures about tax estimates or prior-period revisions.
- Developments in the Seresto matters and SEC inquiry, including any regulatory action, claims, or change in the ability to estimate potential exposure.